Claims
- 1. A compound according to the structure:
- 2. The compound according to claim 1 wherein X is an aminocyclopropyl group.
- 3. A pharmaceutical composition comprising an anti-HIV effective compound according to the structure:
- 4. The composition according to claim 4 wherein X is an aminocyclopropyl group and R1 and R2 are H.
- 5. A method for inhibiting the growth, elaboration and/or the replication of HIV in a patient comprising administering to said patient an anti-HIV effective amount of a compound according to the structure:
- 6. The method according to claim 5 wherein X is an aminocyclopropyl group and R1 and R2 are H.
- 7. A method of reducing the likelihood that an individual will contract HIV or that an HIV infection will mature into AIDS in a patient comprising administering to said individual or said patient in need thereof at least one compound according to the structure:
- 8. The method according to claim 7 wherein wherein X is an aminocyclopropyl group and R1 and R2 are H.
- 9. A pharmaceutical composition comprising a combination of an effective amount of a compound according to the structure:
- 10. The composition according to claim 7 wherein X is an aminocyclopropyl group and R1 and R2 are H.
- 11. The composition of claim 9 wherein said additional agent is a nucleoside reverse transcriptase inhibitor selected from the group consisting of AZT, 3TC, ddC, FTC, D4FC, D4T, ddI, PMPA, Bis(POC)PMPA and mixtures thereof.
- 12. The composition of claim 9 wherein said additional agent is a non-nucleoside reverse transcriptase inhibitor selected from the group consisting of Nevirapine, Delavirdine, Efavirenz, Emivirine, TIBO, TIBO-derivatives, GW420 867X, UC 781 and mixtures thereof.
- 13. The composition of claim 9 wherein said additional agent is a protease inhibitor selected from the group consisting of Saquinavir, Amprenavir, Indinavir, Nelfinavir, Ritonavir, Tipranavir, lopinavir, GW433 908, Lasinavir and mixtures thereof.
- 14. The composition of claim 9 wherein said additional agent is selected from the group consisting of 1,1 ′-azobisformamide, hydroxyurea, LiGLA, and mixtures thereof.
- 15. A method for inhibiting the growth, elaboration and/or the replication of HIV in a patient comprising administering to said patient a combination of an anti-HIV effective amount of a compound according to the structure:
- 16. The method according to claim 15 wherein X is an aminocyclopropyl group and R1 and R2 are H.
- 17. The method of claim 15 wherein said additional agent is a nucleoside reverse transcriptase inhibitor selected from the group consisting of AZT, 3TC, ddC, FTC, D4FC, D4T, ddI, PMPA, Bis(POC)PMPA and mixtures thereof.
- 18. The method of claim 15 wherein said additional agent is a non-nucleoside reverse transcriptase inhibitor selected from the group consisting of Nevirapine, Delavirdine, Efavirenz, Emivirine, TIBO, TIBO-derivatives, GW420 867X, UC 781 and mixtures thereof.
- 19. The method of claim 15 wherein said additional agent is a protease inhibitor selected from the group consisting of Saquinavir, Amprenavir, Indinavir, Nelfinavir, Ritonavir, Tipranavir, lopinavir, GW433 908, Lasinavir and mixtures thereof.
- 20. The method of claim 15 wherein said additional agent is selected from the group consisting of 1,1′-azobisformamide, hydroxyurea, LiGLA, and mixtures thereof.
- 21. The method of claim 16 wherein said additional agent is a nucleoside reverse transcriptase inhibitor selected from the group consisting of AZT, 3TC, ddC, FTC, D4FC, D4T, ddI, PMPA, Bis(POC)PMPA and mixtures thereof.
- 22. The method according to claim 16 wherein said additional agent is selected from the group consisting of AZT, 3TC and mixtures thereof.
- 23. A method of reducing the likelihood that an individual will contract HIV or that an HIV infection will mature into AIDS in a patient comprising administering to said individual or said patient in need thereof a combination of agents comprising an effective amount of at least one compound according to the structure:
- 24. The method according to claim 23 wherein X is an aminocyclopropyl group and R1 and R2 are H.
- 25. The method of claim 23 wherein said additional agent is a nucleoside reverse transcriptase inhibitor selected from the group consisting of AZT, 3TC, ddC, FTC, D4FC, D4T, ddI, PMPA, Bis(POC)PMPA and mixtures thereof.
- 26. The method of claim 23 wherein said additional agent is a non-nucleoside reverse transcriptase inhibitor selected from the group consisting of Nevirapine, Delavirdine, Efavirenz, Emivirine, TIBO, TIBO-derivatives, GW420 867X, UC 781 and mixtures thereof.
- 27. The method of claim 23 wherein said additional agent is a protease inhibitor selected from the group consisting of Saquinavir, Amprenavir, Indinavir, Nelfinavir, Ritonavir, Tipranavir, lopinavir, GW433 908, Lasinavir and mixtures thereof.
- 28. The method of claim 23 wherein said additional agent is selected from the group consisting of 1,1′-azobisformamide, hydroxyurea, LiGLA, and mixtures thereof.
- 29. The method of claim 24 wherein said additional agent is a nucleoside reverse transcriptase inhibitor selected from the group consisting of AZT, 3TC, ddC, FTC, D4FC, D4T, ddI, PMPA, Bis(POC)PMPA and mixtures thereof.
- 30. The method according to claim 24 wherein said additional agent is selected from the group consisting of AZT, 3TC and mixtures thereof.
RELATED APPLICATIONS
[0001] This application claims priority from provisional application no. 60/266,751, filed Feb. 6, 2001.
GRANT SUPPORT
[0002] This invention was supported by NIH Grant GM49551 and AI25899. The Government retains certain rights in the invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60266751 |
Feb 2001 |
US |